Interleukin-38 is elevated in inflammatory bowel diseases and suppresses intestinal inflammation. (March 2020)

• Record Type: Journal Article
• Authors: Xie, Cheng; Yan, Wei; Quan, Runze; Chen, Chaoyue; Tu, Lei; Hou, Xiaohua; Fu, Yu
• Is Part Of: Cytokine. Volume 127(2020)
• Publication Date: 2020-03
• Subjects: Interleukin-38 -- Inflammatory bowel diseases -- Cytokines; IBD inflammatory bowel disease -- CD crohn's disease -- UC ulcerative colitis -- Ctrl control -- BMDM bone marrow derived macrophage -- IL interleukin -- IL-1F IL-1 family -- TNF-α tumor necrosis factor-α -- C-C motif chemokine -- CCL ligand -- DSS dextran sulphate sodium -- LPS lipopolysaccharide -- M-CSF macrophage colony-stimulating factor -- DAI disease activity index -- RT-qPCR quantitative reverse transcription polymerase chain reaction -- WB western blotting -- ELISA enzyme-linked immunosorbent assay; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2019.154963
• Languages: English
• ISSNs: 1043-4666

Abstract

Abstract: There has been no report investigating the role of IL-38 in inflammatory bowel diseases (IBD). Therefore, we investigated the expression of IL-38 in IBD patients and its role in regulating intestinal inflammation. The levels of IL-38 were significantly elevated in the intestine of IBD patients and DSS-induced colitis mice. Immunofluorescence analysis revealed that B cell, not macrophage or T cell, was the source of IL-38 in the intestine. We found that rIL-38 treatment significantly attenuated DSS-induced colitis, including alleviation of weight loss, disease activity index, macroscopic changes and histological damage of colon, along with lower levels of IL-1β and TNF-α. In vitro, rIL-38 significantly decreased the expression of proinflammatory cytokines in LPS-stimulated RAW 264.7 cells and BMDM. This is the first study suggesting that IL-38 may have a protective effect in IBD, which inhibits the production of proinflammatory cytokines from macrophages. IL-38 may represent a promising therapeutic strategy in IBD.